Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.57 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 2/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | IDH2 | P48735 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.51 |
| ▸ | GPR27 | Q9NS67 | 5/20 | 0.50 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138972 | 0.87 | MEN1 (0.57) | MEN1ALDH1A1KMT2AKDM4EGAA | |
| SCHEMBL2567685 | 0.81 | NR1H3 (0.71) | MEN1ALDH1A1KMT2AMAPTFFAR4 | |
| SCHEMBL31301150 | 0.81 | KEAP1 (0.55) | MEN1ALDH1A1KMT2AFFAR4PGR | |
| SCHEMBL16238966 | 0.81 | KEAP1 (0.55) | MEN1ALDH1A1KMT2AFFAR4PGR | |
| SCHEMBL16239045 | 0.81 | KEAP1 (0.55) | MEN1ALDH1A1KMT2AGAAMAPT | |
| SCHEMBL11390047 | 0.79 | ALDH1A1 (0.81) | MEN1ALDH1A1KMT2AKDM4EGAA | |
| SCHEMBL15646797 | 0.78 | KMT2A (0.58) | MEN1ALDH1A1KMT2AKDM4EGAA | |
| SCHEMBL6657103 | 0.77 | GAA (0.72) | MEN1ALDH1A1KMT2AKDM4EGAA | |
| SCHEMBL6976724 | 0.75 | PPARG (0.57) | MAPTFFAR4NR1H3ARNR3C1 | |
| Hydrochloric Acid SCHEMBL10529934 | 0.75 | ALDH1A1 (0.73) | MEN1ALDH1A1KMT2AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-12-19 | — | — | US | disclosed |
| US-12116351-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-10-15 | — | — | US | disclosed |
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-12-01 | — | — | US | disclosed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | disclosed |
| CN-108863959-B | P2X4 receptor antagonists | 日本化学药品株式会社 | 2021-11-30 | — | — | CN | disclosed |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-07-16 | — | — | US | disclosed |
| CN-111333588-A | P2X4 receptor antagonists | 日本化学药品株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-10633349-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-04-28 | — | — | US | disclosed |
| CN-104066724-B | P2X4 receptor antagonists | 日本化学药品株式会社 | 2020-04-17 | — | — | CN | disclosed |
| CN-110483423-A | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO | 2019-11-22 | — | — | CN | disclosed |
| CN-108863959-A | P2X4 RECEPTOR ANTAGONIST | 日本化学药品株式会社 | 2018-11-23 | — | — | CN | disclosed |
| US-20180201587-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2018-07-19 | — | — | US | disclosed |
| US-9969700-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD. (JP) | 2018-05-15 | — | — | US | disclosed |
| EP-2803662-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160280667-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-09-29 | — | — | US | disclosed |
| US-9382236-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-07-05 | — | — | US | disclosed |
| US-20140357858-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2014-12-04 | — | — | US | disclosed |
| EP-2803662-A1 | P2X4 RECEPTOR ANTAGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2014-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | MEN1 3450/4885ALDH1A1 3019/4885KMT2A 2174/4885 |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | MEN1 3285/4885ALDH1A1 3045/4885KMT2A 2558/4885 |
| US-12116351-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | MEN1 3450/4885ALDH1A1 3019/4885KMT2A 2174/4885 |
| US-20160280667-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | MEN1 3353/4885ALDH1A1 3013/4885KMT2A 2156/4885 |
| US-20140357858-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | MEN1 3450/4885ALDH1A1 3019/4885KMT2A 2174/4885 |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | MEN1 3450/4885ALDH1A1 3019/4885KMT2A 2174/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | MEN1 3450/4885ALDH1A1 3019/4885KMT2A 2174/4885 |
| US-10633349-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | MEN1 3450/4885ALDH1A1 3019/4885KMT2A 2174/4885 |
| US-20180201587-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | MEN1 3450/4885ALDH1A1 3019/4885KMT2A 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.